Franck NICOLINI
Hopsices Civils de Lyon · Hospices Civils de Lyon
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Franck NICOLINI as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:52 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT02201459 · Nilotinib ± Peg-IFN for First Line Chronic Phase CML PatientsHospices Civils de Lyon · completed · Chronic Myeloid Leukemia · principal investigator
- Ph2NCT01774630 · Multicenter Single-arm Pilot Study Evaluating Efficacy of Nilotinib in CML Patients With Molecular Relapse After Glivec Discontinuation Within the Context of the STIM Trials (STIM and STIM2)University Hospital, Bordeaux · completed · Leukemia, Myelogenous, Chronic, BCR-ABL Positive · study chair
- Ph2NCT01294618 · Nilotinib + Pegylated Interferon Alpha 2a for Untreated Chronic Phase Chronic Myelogenous LeukemiaHospices Civils de Lyon · completed · Chronic Myelogenous Leukemia · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:52 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:52 UTC. The ranking covers the 200 most relevant of 63 PubMed records, and a shared surname and initials can bring in a namesake. All 63 on PubMed
- 1,245 citationsRCR 27.8
- A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias.N Engl J Med · 2013903 citationsRCR 24.7
- 562 citationsRCR 11.9
- 492 citationsRCR 18.4
- 471 citationsRCR 12.6
- Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group.N Engl J Med · 1997435 citationsRCR 10.4
- Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia.N Engl J Med · 2010305 citationsRCR 6.8
- Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial.Lancet Oncol · 2016222 citationsRCR 7.5
- Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study.Haematologica · 2017140 citationsRCR 4.4
- Treatment-Free Remission After Second-Line Nilotinib Treatment in Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Single-Group, Phase 2, Open-Label Study.Ann Intern Med · 2018122 citationsRCR 4.7